[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intestinal-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intestinal-failure":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,74,99,124,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100556488","weaning-is-winning-wewin-study-100556488",false,"NCT06525753","Weaning is Winning? (WeWin Study)","Weaning is Winning? (WeWin Study): Are Parenteral Nutrition (PN) Graduates Growing up Healthy?","Inclusion Criteria:\n\n* Parenteral Nutrition graduates for at least 1 year, with a history of intestinal failure.\n* Age \\\u003C18 years at time of inclusion.\n\nExclusion criteria:\n\n* No consent provided.","ALL","0 Years","18 Years",{"count":20,"type":21},120,"ESTIMATED","OBSERVATIONAL","We propose a multicenter prospective study on pediatric patients with intestinal failure (IF) who weaned off parenteral nutrition (PN).",[25,26],"Intestinal Failure","Parenteral Nutrition",[28,29],"Quality of Life","Pediatric","RECRUITING","2026-06-19",{"date":33,"type":34},"2026-06-24","ACTUAL",{"date":36,"type":34},"2024-06-01",{"date":38,"type":21},"2034-06-01",{"name":40,"class":41},"The Hospital for Sick Children","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100615794","effect-of-glp-1-on-intestinal-barrier-function-in-sbs-if-patients-a-preliminary-exploration-100615794","NCT07297238","Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.","Therapeutic Efficacy of GLP-1 on Intestinal Barrier Function in Patients With Short Bowel Syndrome and Intestinal Failure: A Preliminary Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants voluntarily provided written informed consent for this trial;\n* Aged 18 to 80 years, inclusive, regardless of gender;\n* With stable vital signs;\n* Diagnosis of SBS-IF, confirmed by existing medical\u002Fsurgical records, receiving parenteral nutrition (PN) due to surgical resection of the small intestine (\\\u003C200 cm from the duodenojejunal flexure), and meeting one of the following criteria:\n\n  * Colon continuity maintained without jejunal\u002Fileal stoma (Type II or III);\n\n    * Presence of a jejunostomy or ileostomy (Type I);\n* Expected requirement of PN for more than 4 weeks, with an average PN caloric intake ≥80%;\n* Ability to comply with the medication dosing and visit schedule;\n* Capacity to accurately describe symptoms, absence of severe infections or respiratory insufficiency, and willingness to cooperate proactively;\n* No history of allergic diseases, non-allergic constitution, and no hypersensitivity to any component of semaglutide injection;\n* No history of drug abuse;\n* Not pregnant or lactating; no pregnancy plans within one month after the trial (applies to both female and male participants);\n* No participation in any other drug trials (including the investigational product in this study) within three months prior to enrollment.\n\nExclusion Criteria:\n\n* Individuals who do not meet the inclusion criteria or are deemed ineligible by the investigator;\n* Poor general condition, inability to accurately describe symptoms, presence of severe infection, respiratory insufficiency, or other conditions that may hinder active cooperation;\n* History of allergic diseases, allergic constitution, or hypersensitivity to drugs structurally related to the investigational product;\n* Patients with malignancy at any site;\n* Those with psychiatric disorders, inability to cooperate, or impaired consciousness;\n* Patients with contraindications to the investigational drug (including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2);\n* Immunodeficiency, or current use of immunosuppressants or corticosteroids;\n* Immediate family members of the sponsor, investigator, or study staff directly involved in the trial;\n* Any other condition considered by the investigator as grounds for exclusion.","80 Years",{"count":52,"type":21},20,"INTERVENTIONAL",[55],"NA","Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcomes will be collected.",[58,25],"Short Bowel Syndrome (SBS)",[60,61,62,63],"GLP-1","short bowel syndrome","intestinal failure","Intestinal Barrier Function","2026-05-27",{"date":66,"type":34},"2026-05-28",{"date":68,"type":34},"2026-01-24",{"date":70,"type":21},"2026-06-30",{"name":72,"class":41},"Jinling Hospital, China",2,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":16,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":53,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100600193","the-lift-echo-last-mile-project-100600193","NCT07094308","The LIFT-ECHO Last Mile Project","Improving Outcomes in Chronic Intestinal Failure Using the ECHO Model: The LIFT-ECHO Last Mile Project","Inclusion Criteria:\n\n* CIF patient participants must meet the following criteria in order to be considered eligible for participation:\n\n  * Individuals of adult age (18 years or older), including pregnant women or Individuals of age \\> 5 years with parental consent and patient assent.\n  * Diagnosis of chronic intestinal failure (ie. on PN \\>6 months with no malignancy, no HIV and a malabsorption or post-surgical diagnosis)\n  * Currently receiving PN from a homecare infusion service company\n* Physician Inclusion Criteria:\n\n  * Physician participants must meet the following criteria in order to be considered eligible for participation:\n\n    * Individuals of adult age (18 years or older), including pregnant women\n    * Hold an MD or DO degree\n    * Be a licensed physician prescriber with a homecare infusion service company\n\nExclusion Criteria:\n\n* Participants meeting one or more of the following criteria will be excluded from participation:\n\n  * Adults unable to consent (individuals with impaired decision-making capacity)\n  * Prisoners\n  * Children \\> 5 years who dissent",true,"5 Years",{"count":84,"type":21},150,[55],"This is a multi-site research study to evaluate the efficacy and effectiveness of the LIFT-ECHO program to improve clinical outcomes in patients and improve patient reported quality of life (PRQOL). LIFT-ECHO (Learn Intestinal Failure Tele-ECHO) is a tele-health learning program whereby non-specialist clinicians meet with and learn from CIF specialist teams with the goal of improving the knowledge of CIF. LIFT-ECHO sessions consist of group discussion of anonymized real-world patient cases, followed by a didactic presentation from an expert in intestinal failure. Sessions are held twice a month and last 60-90 minutes. The study will proceed in three distinct phases, correlating with Project Aims. During phase 1 (Aim 1), an intestinal failure disease activity index (IF-DAI) will be developed as a measure of short- to medium-term clinical activity in CIF patients; this phase will be undertaken through Delphi Rounds. During Phase 2 (corresponding to project Aim 2), the researchers will evaluate the impact of physician participation in LIFT-ECHO on patients with CIF on PN. Lastly, Phase 3, corresponding to Aim 3 will be the dissemination of LIFT-ECHO nationally. For Phase 2, the researchers had originally proposed that patients and physicians will be recruited from the records of Optum Home Infusion services. Patient reported quality of life and clinical status will be assessed using surveys at baseline. Physicians will then be invited to participate in a module of LIFT-ECHO consisting of 8 one- hour-long sessions held over the course of 2-4 months. Patients will then be followed for 12 months to assess if physician participation in LIFT-ECHO improves patient reported quality of life and\u002For treatment efficacy and effectiveness. The main procedures for physician participants in the study include: completion of baseline and monthly surveys, possible participation in an appreciative inquiry workshop and possible participation in a focus group discussion, optional, but encouraged, participation in LIFT-ECHO. The main procedures for patient participants include: completion of surveys at baseline, participation in 12 monthly follow-up phone calls with a study team member. The proposed trial has a total length of 34 months.",[25],"NOT_YET_RECRUITING","2026-03-10",{"date":91,"type":34},"2026-03-12",{"date":93,"type":21},"2026-07-01",{"date":95,"type":21},"2030-06-30",{"name":97,"class":41},"Icahn School of Medicine at Mount Sinai",5,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":53,"phases":108,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":42},"100625450","anabolic-response-to-intravenous-amino-acids-in-chronic-intestinal-failure-patients-100625450","NCT07422792","Anabolic Response To Intravenous Amino Acids In Chronic Intestinal Failure Patients","Anabolic Response To Protein And Assessment Of Metabolic Phenotype In Patients With Home Parenteral Nutrition And Chronic Intestinal Failure","Inclusion Criteria:\n\n\\- Patients with chronic intestinal failure (CIF) receiving home parenteral nutrition.",{"count":107,"type":21},40,[55],"The purpose of this study is to gain insight into the actual protein requirements of patients with chronic intestinal failure (CIF) receiving home parenteral nutrition, which could improve clinical management of these patients. Based on collected data on protein kinetics, the study aims to further refine and personalize nutritional mixtures in patients with CIF. Additional aims include assessment of short-chain fatty acid metabolism and evaluation of gut microbiota function in patients with CIF.",[111,25,112],"Chronic Intestinal Failure","Home Parenteral Nutrition",[26,114],"Intravenous Amino Acids","2026-02-13",{"date":117,"type":34},"2026-02-20",{"date":119,"type":34},"2022-04-01",{"date":121,"type":21},"2027-12-31",{"name":123,"class":41},"Institute of Oncology Ljubljana",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":53,"phases":134,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":42},"100624818","ai-driven-total-parenteral-nutrition-platform-100624818","NCT07414576","AI-driven Total Parenteral Nutrition Platform","Clinical Decision Support for Total Parenteral Nutrition Constituents in Neonatal Intensive Care Unit (NICU) Patients: A Pilot Study","Inclusion Criteria:\n\n* Any newborns or infants requiring total parenteral nutrition in a neonatal ICU that performs daily laboratory tests\n* 6-month old at the time of admission\n* Any gestational age or birthweight\n* Any race or sex\n\nExclusion Criteria:\n\n\\- Infants deem unfit for the suggested TPN due to safety concerns by physicians","6 Months",{"count":133,"type":21},260,[55],"This study tests whether an artificial intelligence (AI) tool can help doctors order total parenteral nutrition (TPN) for babies in the neonatal intensive care unit (NICU). Premature babies often cannot eat by mouth and need nutrition delivered through an IV. Ordering TPN is complex, time-consuming, and mistakes can happen. This study will test an AI tool that suggests TPN formulas to doctors based on each baby's lab values and health information. Doctors can accept, change, or reject the suggestions at any time. The main goal is to measure how often doctors accept the AI suggestions. The study will also track time to complete TPN orders, weight changes, days on TPN, whether lab values stay in normal ranges, provider satisfaction, and baby health outcomes including complications such as lung disease, brain bleeding, infections, and other conditions common in premature babies. Babies admitted to the NICU who need TPN may participate if their doctors agree to use the tool. Each baby will be in the study while they need TPN, typically about 14 days. The AI tool only makes suggestions and does not replace doctor decision-making. All other care remains the same as standard practice.",[25],[138],"parenteral nutrition","2026-02-10",{"date":141,"type":34},"2026-02-17",{"date":143,"type":34},"2026-01-21",{"date":145,"type":21},"2027-02-21",{"name":147,"class":148},"Takeoff41, Inc.","INDUSTRY",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":42},"100608780","effect-of-parenteral-support-on-fibroscan-in-short-bowel-syndrome-100608780","NCT07206004","Effect of Parenteral Support on FibroScan in Short Bowel Syndrome","Effect of Parenteral Nutrition\u002FFluids on FibroScan Results in Patients With Short Bowel Syndrome","Inclusion Criteria:\n\n* Adult patients (≥18 years) with short bowel syndrome with capacity to give consent\n* Patients receiving regular PS (≥4 days\u002Fweek and ≥10 liters\u002Fweek)\n* Stable clinical condition\n\nExclusion Criteria:\n\n* Known liver cirrhosis\n* Active infection, severe dehydration, or electrolyte disturbances\n* Pregnancy\n* Receiving IV fluids or medications on study day\n* Tapered infusion rate prior to disconnection",{"count":52,"type":21},"Home Parenteral Support (HPS) is a life-sustaining treatment for patients with short bowel syndrome and intestinal failure. This study aims to investigate how administration of parenteral support affects FibroScan results in order to determine optimal timing of liver assessment in this patient population.",[159,25,160],"Short Bowel Syndrome","Liver Diseases",[162,163,138,62,164],"FibroScan","transient elastography","hepatic fibrosis","2025-09-25",{"date":167,"type":34},"2025-10-03",{"date":169,"type":21},"2026-02",{"date":171,"type":21},"2027-08",{"name":173,"class":41},"Rigshospitalet, Denmark"]